Sands Capital Alternatives
ARLINGTON, VAfiles as Sands Capital Alternatives, LLC
$614m in 24 US stocks at the end of 30 June 2026. The top 10 are 80.8% of the money. It changed about 25.3% of the portfolio this quarter.
Value
$614m
Stocks
24
Top 10 share
80.8%
Turnover
25.3%
What changed this quarter
New
Bought for the first time this quarter.
- Alamar BiosciencesALMR18.7% of the fund
- Odyssey TherapeuticsODTX2.7% of the fund
- Cerebras SystemsCBRS1.2% of the fund
Added
Bought more of a stock they already held.
- Nu HoldingsNU15.4% of the fund+9%
- KlaviyoKVYO9.7% of the fund+8%
- DoorDashDASH3.8% of the fund+15%
- CoupangCPNG3.8% of the fund+31%
- ToastTOST1.7% of the fund+21%
- ServiceTitanTTAN1.3% of the fund+21%
- SnowflakeSNOW1.0% of the fund+21%
- monday.comMNDY1.0% of the fund+21%
- Acrivon TherapeuticsACRV0.7% of the fund+8%
- FigmaFIG<0.1% of the fund+21%
Cut
Sold some of their stake.
- DatadogDDOG3.4% of the fund-6%
- SamsaraIOT2.7% of the fund-8%
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Alamar BiosciencesALMR
- Share
- 18.7%
- Value
- $115m
- Shares
- 4,230,926
New
- Odyssey TherapeuticsODTX
- Share
- 2.7%
- Value
- $16m
- Shares
- 875,000
New
- Cerebras SystemsCBRS
- Share
- 1.2%
- Value
- $7m
- Shares
- 32,825
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Alamar BiosciencesALMR | 18.7% | $115m | 4,230,926 | New |
| Nu HoldingsNU | 15.4% | $95m | 7,094,952 | +9% |
| KlaviyoKVYO | 9.7% | $59m | 3,928,146 | +8% |
| Beta BionicsBBNX | 9.5% | $58m | 3,708,043 | Held |
| SpyGlass PharmaSGP | 9.1% | $56m | 2,500,012 | Held |
| Inhibikase TherapeuticsIKT | 4.3% | $26m | 13,018,965 | Held |
| DoorDashDASH | 3.8% | $24m | 127,562 | +15% |
| CoupangCPNG | 3.8% | $23m | 1,329,314 | +31% |
| DatadogDDOG | 3.4% | $21m | 80,851 | -6% |
| BioAge LabsBIOA | 3.1% | $19m | 786,353 | Held |
| 10x GenomicsTXG | 3.0% | $18m | 481,770 | Held |
| SamsaraIOT | 2.7% | $17m | 515,658 | -8% |
| Odyssey TherapeuticsODTX | 2.7% | $16m | 875,000 | New |
| ToastTOST | 1.7% | $10m | 364,879 | +21% |
| Acumen PharmaceuticalsABOS | 1.6% | $10m | 3,720,105 | Held |
| ServiceTitanTTAN | 1.3% | $8m | 108,545 | +21% |
| Cerebras SystemsCBRS | 1.2% | $7m | 32,825 | New |
| SnowflakeSNOW | 1.0% | $6m | 24,498 | +21% |
| monday.comMNDY | 1.0% | $6m | 81,982 | +21% |
| Tarsus PharmaceuticalsTARS | 0.9% | $5m | 85,000 | Held |
| Taysha Gene TherapiesTSHA | 0.8% | $5m | 724,873 | Held |
| Candel TherapeuticsCADL | 0.7% | $4m | 405,837 | Held |
| Acrivon TherapeuticsACRV | 0.7% | $4m | 2,289,271 | +8% |
| FigmaFIG | <0.1% | $400,965 | 22,165 | +21% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 20.8% since 30 June 2025.
Where the money is
Health care55.0%
Technology20.3%
Financial services17.1%
Retail & consumer7.6%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.